Quarterly ResultMay 6, 2026, 04:33 PM
Innoviva Swings to Q1 Net Income of $186.6M; Revenue Up 10.6%
AI Summary
Innoviva reported a significant turnaround in its first quarter 2026 financial results, swinging to a net income of $186.6 million, compared to a net loss of $46.6 million in the prior year period. Total revenue increased by 10.6% to $98.0 million, driven by a substantial 36.6% growth in net product sales, particularly from XACDURO®. The positive financial performance was also significantly boosted by favorable changes in the fair values of equity method and long-term investments. The company also announced the FDA approval of NUZOLVENCE® in December 2025, with availability expected in the second half of 2026.
Key Highlights
- Net income was $186.6 million for Q1 2026, a significant improvement from a $46.6 million net loss in Q1 2025.
- Total revenue increased 10.6% to $98.0 million in Q1 2026 from $88.6 million in Q1 2025.
- Basic EPS was $2.52 in Q1 2026, compared to a basic EPS loss of $0.74 in Q1 2025.
- Net product sales grew 36.6% to $41.4 million in Q1 2026 from $30.3 million in Q1 2025.
- XACDURO® net product sales surged 132.2% to $18.1 million in Q1 2026.
- Royalty revenue decreased 4.6% to $55.2 million in Q1 2026 from $57.8 million in Q1 2025.
- Cash and cash equivalents rose to $603.1 million as of March 31, 2026.
- The company repurchased $20.2 million of common stock in Q1 2026.
Price Impact
More from INVA